Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes

被引：9

作者：

Toprani, A. ^{[1
]}

Fonseca, V. ^{[2
]}

机构：

[1] Tulane Univ, Hlth Sci Ctr, Dept Family & Community Med, Sect Prevent Med, New Orleans, LA 70112 USA

[2] Tulane Univ, Hlth Sci Ctr, Endocrinol Sect, Dept Med, New Orleans, LA 70112 USA

来源：

DIABETES OBESITY & METABOLISM | 2011年 / 13卷 / 03期

基金：

美国国家卫生研究院;

关键词：

adverse effect; antihyperglycaemic agents; congestive heart failure; glitazone; thiazolidinedione; type; 2; diabetes; ALBUMIN EXCRETION; ROSIGLITAZONE; PIOGLITAZONE; RISK; HOSPITALIZATION; METFORMIN; OUTCOMES;

D O I：

10.1111/j.1463-1326.2010.01348.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Methods: A retrospective cohort study of all male patients with type 2 diabetes seen in the South Central US Veterans Administration health care network between 1 October 1996 and 31 December 2004. We constructed a Cox proportional hazards model to evaluate the impact of TZD therapy on time to incidence of CHF. Results: Of 3956 patients, 29% (n = 1157) developed CHF during the study period. The incidence of CHF was higher in patients who received TZD medications than in those who received TZDs. After adjustment for multiple cardiac risk factors, the hazard ratio for the development of CHF for TZD versus non-TZD-treated patients was 0.69 with a 95% confidence interval of 0.60-0.79. Conclusions: Patients in this cohort who received TZD medications had a lower incidence of heart failure than patients who did not receive TZDs.

引用

页码：276 / 280

页数：5

共 50 条

[1] Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes (vol 13, pg 276, 2011)
Fonseca, Vivian
[J]. DIABETES OBESITY & METABOLISM, 2012, 14 (04): : 386 - 386
[2] Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus
Filion, Kristian B.
Joseph, Lawrence
Boivin, Jean-Francois
Suissa, Samy
Brophy, James M.
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (08) : 785 - 796
[3] Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
Granberry, Mark C.
Hawkins, Jason B.
Franks, Amy M.
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (09) : 931 - 936
[4] The incidence of congestive heart failure in type 2 diabetes
Nichols, GA
Gullion, CM
Koro, CE
Ephross, SA
Brown, JB
[J]. DIABETES CARE, 2004, 27 (08) : 1879 - 1884
[5] Do thiazolidinediones cause congestive, heart failure?
Kennedy, FP
[J]. MAYO CLINIC PROCEEDINGS, 2003, 78 (09) : 1076 - 1077
[6] Thiazolidinediones: congestive heart failure and pulmonary oedema
[J]. Reactions Weekly, 2003, 969 (1) : 5 - 5
[7] Thiazolidinediones for type 2 diabetes - All glitazones may exacerbate heart failure
Benbow, A
Stewart, M
Yeoman, G
[J]. BRITISH MEDICAL JOURNAL, 2001, 322 (7280): : 236 - 236
[8] Thiazolidinediones are associated with increased risk of heart failure in patients with type 2 diabetes
Delea, TE
Hagiwara, M
Edelsberg, JS
Oster, G
Phillips, LS
[J]. DIABETES, 2002, 51 : A95 - A95
[9] Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes
Conradi, Philipp
[J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2021, 118 (25): : 434 - 434
[10] Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes
Seoudy, Anna Katharina
Schulte, Dominik M.
Hollstein, Tim
Boehm, Ruwen
Cascorbi, Ingolf
Laudes, Matthias
[J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2021, 118 (08): : 122 - +

← 1 2 3 4 5 →